anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 222,811-222,840
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

222,811-222,840 of 303,780

filter-aware
10
The slide uses a problem-solution framework to justify the engineering approach for each therapeutic program.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
11
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
12
Uses a vertical process flow diagram to represent development stage gates.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
13
Uses a before-after-framing style comparison to illustrate the mechanism of action differentiation.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
14
The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
15
The table uses a structured approach to categorize clinical trials into Foundational, Alternative Dosing, and Registrational enabling.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
16
The slide uses a process flow diagram to illustrate the progression of the clinical trial cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
17
The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
18
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Loop · Before After1 hit
22
The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram for the mechanistic combinations.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
25
The slide outlines the clinical strategy for optimizing nemvaleukin dosing, referencing specific clinical trials (ARTISTRY-3 and ARTISTRY-6).Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
26
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
27
The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory functions.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
29
Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
30
Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
31
The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream effects.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
32
The slide uses a process flow diagram to explain the therapeutic mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
33
Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
34
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
36
Uses a numbered list format to highlight key company facts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
37
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
01
Slide 1
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
02
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit